1Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol,2002,3(11) : 672-683.
2Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol, 2001,61 ( 3 ): 253-270.
3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21(12): 2237-2246.
4Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitahine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial -INTACT 1. J Clin Oncol. 2004 Mar 1;22(5): 777-784.
5Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 2. J Clin Oncol,2004,22(5):785-794.
6Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase Ⅲ clinical trials. Semin Oncol,2001,28(6): 620-625.
7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
8Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE 522, and conventional anticancer agents. Clin Cancer Res, 2002,8 (7) : 24
9Crul M, de Klerk GJ, Swart M, et al. Phase Ⅰ clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol,2002,20(11): 2726-2735.
10Baselga J, Rischin D, Ranson M, et al. Phase Ⅰ safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol, 2002
